Expression of arylamine N-acetyltransferase 2 activity in immortalized human bronchial epithelial cells [PDF]
Toxicol Appl Pharmacol, 2022 Lung cancer is the leading cause of cancer deaths in the United States with high incidence in tobacco smokers. Arylamine N-acetyltransferase 2 (NAT2) is a xenobiotic enzyme that catalyzes both N- and O-acetylation of carcinogens present in tobacco smoke ...
Doll, Mark A. +4 more
core +2 more sources
Frontiers in Pharmacology, 2022 Arylamine N-acetyltransferases catalyze the transfer of acetyl groups from the endogenous cofactor acetyl coenzyme A (AcCoA) to arylamine (N-acetylation) and N-hydroxy-arylamine (O-acetylation) acceptors.
Mariam R Habil +2 more
exaly +3 more sources
Dataset for proteomic analysis of arylamine N-acetyltransferase 1 knockout MDA-MB-231 breast cancer cells [PDF]
Data in Brief, 2022 Arylamine N-acetyltransferase 1 (NAT1) is frequently upregulated in breast cancer. An unbiased analysis of proteomes of parental MDA-MB-231 breast cancer cells and two separate NAT1 knockout (KO) cell lines were performed. Among 4,890 proteins identified,
Kyung U. Hong +8 more
doaj +2 more sources
Non-coding and intergenic genetic variants of human arylamine N-acetyltransferase 2 (NAT2) gene are associated with differential plasma lipid and cholesterol levels and cardiometabolic disorders [PDF]
Frontiers in Pharmacology, 2023 Arylamine N-acetyltransferase 2 (NAT2) is a phase II metabolic enzyme, best known for metabolism of aromatic amines and hydrazines. Genetic variants occurring in the NAT2 coding region have been well-defined and are known to affect the enzyme activity or
Kyung U. Hong +2 more
doaj +2 more sources
Carcinogenic potential of arylamine N-acetyltransferase in Asian populations
Journal of Cancer Research and Practice, 2018 Arylamine N-acetyltransferase (NAT) is a phase II metabolizing enzyme, which belongs to the transferase family; specifically those acyltransferases which transfer various groups except aminoacyl. NATs are found in both prokaryotes and eukaryotes.
Saba Kabir, Abdul Rehman
doaj +2 more sources
Humans and Chimpanzees Display Opposite Patterns of Diversity in Arylamine N-Acetyltransferase Genes [PDF]
G3: Genes, Genomes, Genetics, 2019 Among the many genes involved in the metabolism of therapeutic drugs, human arylamine N-acetyltransferases (NATs) genes have been extensively studied, due to their medical importance both in pharmacogenetics and disease epidemiology.
Christelle Vangenot +9 more
doaj +2 more sources
Effect arylamine N-acetyltransferase 1 on morphology, adhesion, migration, and invasion of MDA-MB-231 cells: role of matrix metalloproteinases and integrin αV [PDF]
Cell Adhesion & Migration, 2020 Reducted arylamine N-acetyltransferase (NAT1) in breast cancers is associated with poor patient survival. NAT1 has also been associated with changes in cancer cell survival and invasion both in vitro and in vivo.
Pengcheng Li +2 more
doaj +2 more sources
Proteomic analysis of arylamine N-acetyltransferase 1 knockout breast cancer cells: Implications in immune evasion and mitochondrial biogenesis [PDF]
Toxicology Reports, 2022 Previous studies have shown that inhibition or depletion of N-acetyltransferase 1 (NAT1) in breast cancer cell lines leads to growth retardation both in vitro and in vivo, suggesting that NAT1 contributes to rapid growth of breast cancer cells.
Kyung U. Hong +8 more
doaj +2 more sources
Trimodal distribution of arylamine N-acetyltransferase 1 mRNA in breast cancer tumors: association with overall survival and drug resistance [PDF]
BMC Genomics, 2018 Background Arylamine N-acetyltransferase 1 (NAT1) is a drug metabolizing enzyme that has been associated with cancer cell proliferation in vitro and with survival in vivo.
Rodney F. Minchin, Neville J. Butcher
doaj +2 more sources
Acta Pharmaceutica Sinica B, 2017 Cryopreserved human hepatocytes were used to investigate the role of arylamine N-acetyltransferase 2 (NAT2; EC 2.3.1.5) polymorphism on the N-acetylation of isoniazid (INH).
Mark A. Doll +3 more
doaj +2 more sources